*67% of patients with commercial insurance have 1st line coverage.1
*As evidenced by ARR, MRI (Gd+ T1 and T2 lesions), and 3- and 6-month CDP.2
Actual patient taking KESIMPTA who was compensated for time. Individual results may vary.
"I'm glad I started RMS treatment with KESIMPTA."
Walt: husband • dad • aeronautical engineer • taking KESIMPTA first line
MEET REAL RELAPSING MS PATIENTS
WHO ARE READY
FOR KESIMPTA
Actual patient taking KESIMPTA who was compensated for time. Individual results may vary.
ALONGSIDE™ KESIMPTA IS HERE TO SUPPORT YOUR PATIENTS
Leticia, Alongside Coordinator
80% OF ELIGIBLE PATIENTS WITH COMMERCIAL INSURANCE CAN START KESIMPTA IN 4 DAYS OR LESS THROUGH OUR BRIDGE PROGRAM4
Based on prescription data collected from April to September 2023.
YOUR ELIGIBLE, COMMERCIALLY INSURED PATIENTS PAY AS LITTLE AS A $0† COPAY
†Limitations apply. Offer not valid under Medicare, Medicaid, or any other federal or state health insurance program. Patients with commercial insurance who are initially denied coverage may receive free KESIMPTA for up to 12 months while seeking coverage. Patients with commercial insurance who have coverage for KESIMPTA may receive up to $18,000 in annual copay benefits. Novartis reserves the right to rescind, revoke, or amend this program without notice. Additional limitations may apply. See complete Terms & Conditions at start.kesimpta.com.
ARR, annualized relapse rate; CDP, confirmed disability progression; DMT, disease-modifying therapy; Gd+, gadolinium-enhancing; MOA, mechanism of action; MRI, magnetic resonance imaging; MS, multiple sclerosis; RMS, relapsing multiple sclerosis; SC, subcutaneous.